A041-04 DART PART 1 FINAL 21Sept2016 Supp from The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Supplemental data for DART Part 1 manuscript. Contains 1 figure and 3 tables. Supplemental Figure 1: Percent change from baseline in serum receptor expression. Samples were taken at cycle 1 day 1 (baseline), cycle 2 day 1, cycle 2 day 8, cycle 3 day 1, and the last visit. Percent change from baseline was calculated for each patient and averaged across all patients. (A) Serum VEGFR3 receptor expression (B) Serum VEGFR2 receptor expression. Supplemental Table 1: Management of Adverse Events Related to Dalantercept/Placebo Supplemental Table 2: Summary Pharmacokinetic Parameters for Dalantercept plus Axitinib Supplemental Table 3: Biomarker Expression Levels in Biopsied Tissue Samples